<DOC>
	<DOCNO>NCT01461577</DOCNO>
	<brief_summary>Primary Objective : - To assess efficacy insulin glargine measure change HbA1c level baseline type 2 diabetes mellitus ( T2DM ) patient follow GLP-1 failure . Secondary Objective : - To determine change glycemic control , safety , treatment satisfaction insulin glargine use patient follow GLP-1 failure .</brief_summary>
	<brief_title>Effectiveness Safety Treatment Insulin Glargine Type 2 Diabetes Mellitus Following Glucagon-like Peptide-1 ( GLP-1 ) Failure</brief_title>
	<detailed_description>1-2 week screen period , 24 week treatment period , 1 week follow-up period</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Glargine</mesh_term>
	<mesh_term>Glucagon</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<criteria>Inclusion criterion : Patients age ≥30 ≤75 year type 2 diabetes mellitus ( T2DM ) Hemoglobin A1c ( glycosylated hemoglobin ; HbA1c ) level measure screen ≥7.5 % Continuous treatment stable dos GLP1 analogue &gt; 3 month prior enrollment ( patient also use oral antihyperglycemic drug [ OADs ] , continuous treatment stable dos OADs &gt; 3 month prior enrollment ) Exclusion criterion : Inpatient T2DM Diabetes T2DM ( e.g . secondary pancreatic disorder , drug chemical agent intake ) Fasting plasma glucose ( FPG ) level &lt; 130mg/dL Body mass index ( BMI ) &gt; 28 kg/m2 Patients use thiazolidinediones last 3 month prior enrollment Use treatment weight loss last 3 month prior enrollment Treatment systemic corticosteroid within 3 month prior enrollment Patients use nonselective ßblockers Likelihood require treatment study period drug permit clinical trial protocol Most recent ophthalmologic examination &gt; 6 month prior enrollment Diabetic retinopathy surgical treatment ( last photocoagulation vitrectomy ) 3 month enrollment may require surgical treatment Proliferative diabetic retinopathy unstable rapidly progressive retinopathy Impaired renal function define , limited , serum creatinine ≥1.3 mg/dL [ male ] ≥1.2 mg/dL [ female ] presence macroproteinuria ( &gt; 1 g/day ) Active liver disease include hepatic cirrhosis , hepatic failure , hepatitis alanine transaminase ( ALT ) aspartate aminotransferase ( AST ) &gt; 2 time upper limit total bilirubin &gt; 1.5 time upper limit normal ( except case Gilbert 's syndrome ) enrollment Have condition ( include know substance alcohol abuse psychiatric disorder ) preclude patient follow complete study protocol Any medical condition may influence HbA1c rate Currently undergo therapy malignancy may affect study evaluation Use investigational product and/or device within 2 month prior enrollment History ketoacidosis hyperosmolar hyperglycemic state previous 12 month prior enrollment History stroke , myocardial infarction , angina pectoris , coronary artery bypass graft percutaneous transluminal coronary angioplasty within previous 12 month prior enrollment History congestive heart failure History hypoglycemia unawareness unexplained hypoglycemia previous 12 month prior enrollment Hemoglobinopathy hemolytic anemia , transfusion blood plasma product within 3 month prior enrollment Known hypersensitivity / intolerance insulin glargine excipients History pancreatitis Pregnant breastfeeding woman ( woman childbearing potential must negative pregnancy test study entry medically approve contraception method ) Shift worker regularly work nighttime shift The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>